Roumie CL, Hung AM, Russell GB, et al. - In the SPRINT (Systolic Blood Pressure Intervention Trial), decreased cardiovascular outcomes was established. Researchers here examined this randomized trial that compared intensive blood pressure strategy (systolic blood pressure < 120 mm Hg) vs standard strategy (< 140 mm Hg) for the incidence of diabetes mellitus: fasting blood glucose ≥ 126 mg/dL (6.99 mmol/L), diabetes mellitus self-report, or new use of hypoglycemics. They assessed those participants who were ≥ 50 years of age, with systolic 130 to 180 mm Hg and increased cardiovascular risk, and did not report diabetes mellitus, polycystic kidney disease, proteinuria > 1 g/d, heart failure, dementia, or stroke. Following exclusion, they assessed 4,187 and 4,193 participants assigned to intensive and standard strategies, respectively. Development of 299 diabetes mellitus events was reported (2.3% per year) in intensive vs 251 events (1.9% per year) in standard, rates of 22.6 (20.2–25.3) vs 19.0 (16.8–21.5) events per 1,000 person-years of treatment, respectively. For intensive and standard strategies, impaired fasting glucose rates of 26.4 (24.9–28.0) and 22.5 (21.1–24.1) per 100 person-years were reported. These findings suggest no association of intensive treatment strategy with increased diabetes mellitus but with more impaired fasting glucose. They recommend factoring the risks and benefits of intensive blood pressure targets into individualized patient treatment goals.